Answers in CME

CME in Minutes: Education in Oncology & Hematology

Science EN ↓ 140 episodes

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access...

Author

Answers in CME

Episodes

Bridging Clinic and OR: A Dialogue on the Emerging Role of Neoadjuvant HER2-Directed ADCs in HER2+ Breast Cancer 08.04.2026 25:28

Please visit answersincme.com/FBF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Paolo Tarantino, MD, PhD and Christopher Vetter, MD, MSc, FACS. In this activity, experts in breast cancer discuss the role of neoadjuvant human epidermal growth factor receptor 2 (HER2)–directed antibody-drug conjugates in HER2+ early-stage bre...

Survivorship Strategies for Patients on First-Line HER2+ mBC Maintenance Therapies: Practical Guidance on Monitoring and AE Management 01.04.2026 30:26

Please visit answersincme.com/860/100850799-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Jane Meisel, MD, FASCO. In this activity, experts in breast cancer discuss practical approaches to optimize survivorship and patient care for patients with HER2-positive metastatic breast...

When Form Maximizes Function: Examining the Role of Subcutaneous Immune Checkpoint Inhibitors in Oncology Practice 24.03.2026 15:58

Please visit answersincme.com/KWA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Benjamin Levy, MD, FASCO. In this activity, an expert in oncology discusses the use of subcutaneous immune checkpoint inhibitors. Upon completion of this activity, participants should be better able to: Describe the rationale for subcutaneous (S...

HER2 in Focus: Guiding Bladder Cancer Treatment Personalization in the Era of Antibody-Drug Conjugates 20.03.2026 1:08:01

Please visit answersincme.com/860/101393625-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Yohann Loriot, MD, PhD and Andrea Necchi, MD. In this activity, experts in genitourinary cancers examine evidence-based strategies for integrating HER2 biomarker testing and HER2-directed antibody-drug conjugates into personalized,...

Contextualizing the Data for Novel First-Line HER2+ mBC Maintenance Therapies: How Might the Treatment Paradigm Change? 20.03.2026 26:12

Please visit answersincme.com/860/100850799-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Otto Metzger, MD. In this activity, experts in breast cancer discuss the clinical implications of recent data on first-line maintenance strategies in HER2-positive metastatic breast cancer...

Bridging Evidence and Practice: Updates on HER2-Targeted ADCs for Gastric/GEJ Adenocarcinoma 18.03.2026 16:38

Please visit answersincme.com/HAC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Kohei Shitara, MD, PhD. In this activity, an expert in gastrointestinal oncology discusses the latest data for the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be...

Facing Therapeutic Resistance to Maintenance Therapy: The Need for Novel Strategies in HER2+ mBC 13.03.2026 24:32

Please visit answersincme.com/860/100850799-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Sara A. Hurvitz, MD, FACP. In this activity, experts in breast cancer discuss the evolving standard-of-care and emerging first-line maintenance strategies in HER2-positive metastatic breas...

RAS(ON) Inhibition: On the Path to Overcoming Therapeutic Resistance and Targeting More Variants in KRAS-Mutated NSCLC 02.03.2026 1:01:59

Please visit answersincme.com/860/120773-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alex Spira, MD, PhD, FASCO; and Kathryn C. Arbour, MD. In this activity "In this activity, experts in oncology discuss the evolving role of RAS(ON) inhibitors in shaping future treatment strategies for patients with KRAS-mutated non–s...

Rethinking HER2 Status: Practical Testing Considerations for HER2-Low and -Ultralow Advanced Breast Cancer 19.02.2026 20:49

Please visit answersincme.com/CZS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Giuseppe Curigliano, MD, PhD. In this activity, an expert in oncology discusses the differentiation of patients with HER2-low/ultralow/negative advanced breast cancer and treatment with antibody-drug conjugates. Upon completion of this activity,...

Breaking Old Habits in Lung Cancer Detection: Expanding Screening Efforts Among At-Risk Populations 10.02.2026 18:20

Please visit answersincme.com/RCG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Raymond Osarogiagbon, MD, MBBS, FACP, FASCO; and Michael Gieske, MD. In this activity, experts in lung cancer discuss practical strategies for lung cancer screening. Upon completion of this activity, participants should be better able to: Recogn...

Getting Practical About Optimizing Management of Stage II and III NSCLC: Expert Guidance to Elevate Care 09.02.2026 35:26

Please visit answersincme.com/860/97150451-replay4 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; Kristin Higgins, MD and Nicolas Girard, MD, PhD. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss real-world learner questions to provide evidence-based strategies for applying...

ADC-elerating Progress: Targeting TROP2 in Triple-Negative Breast Cancer to Improve Front-Line Care 03.02.2026 1:00:37

Please visit answersincme.com/860/29264-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aditya Bardia, MD and Tiffany A. Traina, MD, FASCO. In this activity, experts in breast cancer share evidence-based insights on integrating current and emerging TROP2-directed antibody-drug conjugates (ADCs) into real-world triple-nega...

Advancing Care in Unresectable Stage III NSCLC: Consolidation Immunotherapy and Beyond 28.01.2026 28:54

Please visit answersincme.com/860/97150451-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD and Kristin Higgins, MD. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical steps for integrating consolidation immunotherapy in unresectable stage III NSCLC. Upon comple...

Rapid Roundup 2025: Hot Topics in Myelodysplastic Syndromes and Myelofibrosis 19.01.2026 32:17

Please visit answersincme.com/860/99519635-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Guillermo Garcia-Manero, MD and John Mascarenhas, MD. In this activity, experts in Myelodysplastic Syndromes discuss the latest data for the treatment of anemia in patients with MDS and myelofibrosis. Upon completion of this activit...

Advancing Holistic First-Line Care in Advanced Urothelial Carcinoma: Guideline-Based Strategies and Best Practices in Adverse Event Management 13.01.2026 23:30

Please visit answersincme.com/KEC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jonathan E. Rosenberg, MD and Dayna A. Leis, NP. In this activity, experts in genitourinary oncology management discuss evidence-based first-line approaches for advanced urothelial carcinoma (UC) and share practical strategies to recognize and m...

Ticiana Leal, MD - Translating Trials to Treatment: Practical Strategies for Immunotherapy Integration in Limited-Stage and Extensive-Stage SCLC 08.01.2026 18:42

Please visit answersincme.com/JRV860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lung cancer discusses the use of immunotherapy in clinical practice for patients with limited-stage (LS) and extended-stage (ES) small-cell lung cancer (SCLC). Upon completion of this activity, participants should be better abl...

Carolyn Owen, MD, MDres(UK), FRCPC - Innovations in Relapsed/Refractory CLL/SLL Therapy: Integrating Non-Covalent BTK Inhibitors for Improved Outcomes 06.01.2026 14:14

Please visit answersincme.com/FJJ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in hematology and oncology discusses the use of noncovalent BTK inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL) after at least 2 prior lines of therapy. Upo...

Prof. Solange Peters, MD, PhD / Alfredo Addeo, MD - Patient-Centered Strategies in Early-Stage NSCLC: Navigating the Treatment Journey Together 17.12.2025 39:01

Please visit answersincme.com/860/97150451-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss treatment strategies for resectable and unresectable disease while highlighting ways to optimize long-term outcomes. Upon completion of this activity, participants should b...

Peter R. Galle, MD, PhD - Expanding Options, Elevating Outcomes: The Role of First-Line Combination Therapy for Unresectable HCC 16.12.2025 11:00

Please visit answersincme.com/UNP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in hepatology discusses the latest evidence and guideline recommendations for the first-line treatment of unresectable hepatocellular carcinoma. Upon completion of this activity, participants should be better able to: Review the g...

Jacob Sands, MD / Benjamin Levy, MD, FASCO - What’s Now and What’s Next for ADCs in NSCLC? Integrating HER2- and TROP2-Targeted Therapies Into the Evolving Treatment Landscape 15.12.2025 1:03:43

Please visit answersincme.com/860/99120473-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in oncology discuss the latest advances in HER2- and TROP2-directed ADCs for the management of advanced NSCLC, and how these approved and emerging ADCs may impact patients’ treatment algorithms. Upon completion of this...

Taofeek K. Owonikoko, MD, PhD, MS / Ticiana Leal, MD - New Frontiers in Small Cell Lung Cancer: Getting Ready for the Emergence of B7-H3–Directed ADCs 12.12.2025 1:01:35

Please visit answersincme.com/860/99097105-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in small cell lung cancer (SCLC) discuss the pathophysiologic rationale, emerging clinical evidence, and potential future role for B7-H3–directed antibody-drug conjugates in extensive-stage SCLC. Upon completion of this...

Caitlin Costello, MD / Paul G. Richardson, MD - ‘Four’ Every Patient: Maximizing Outcomes in Newly Diagnosed Multiple Myeloma Care With Anti-CD38 Monoclonal Antibody–Based Quadruplet Therapies 10.12.2025 1:13:41

Please visit answersincme.com/860/IME-2025-21131-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in hematology/oncology discuss use of anti-CD38 monoclonal antibody–based quadruplet regimens in the treatment of patients with newly diagnosed multiple myeloma (NDMM). Upon completion of this activity, participan...

Marina Chiara Garassino, MD / Edgardo S. Santos, MD, FACP, FASCO - Personalizing Care in Squamous NSCLC: From Test Results to Tailored Immunotherapy 09.12.2025 1:03:38

Please visit answersincme.com/860/MED-ONC-03650-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in the management of squamous non–small-cell lung cancer (NSCLC) discuss guideline-based treatment selection, clinical factors guiding the personalization of immunotherapy plans, and long-term strategies to optimiz...

Prof. Solange Peters, MD, PhD / David Harpole, MD - Perioperative Immunotherapy: A Multidisciplinary Blueprint for Optimizing Outcomes in Resectable NSCLC 08.12.2025 31:57

Please visit answersincme.com/860/97150451-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss case-based strategies for integrating perioperative immunotherapy in resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the i...

Charu Aggarwal, MD, MPH / Benjamin Levy, MD, FASCO - Rapid Roundup in NSCLC: Keeping Up with ADC Therapies Driving Precision Lung Cancer Care 05.12.2025 1:00:55

Please visit answersincme.com/860/IME-69386-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in NSCLC discuss how to harness targeted ADCs with practical, case-based insights to personalize care and improve outcomes in advanced lung cancer. Upon completion of this activity, participants should be better able...